RELIEVE-HF TRIAL: REducing Lung congestIon symptoms using the v-wavE shunt in adVancEd Heart Failure Save

Date Added
January 14th, 2020
PRO Number
Pro00095660
Researcher
Sheldon Litwin

List of Studies

Silhouette
Keywords
Cardiovascular, Heart, Hypertension/ High Blood Pressure
Summary

The purpose of the study is to evaluate the safety and how well the V-Wave Interatrial Shunt works. The study will also look at information obtained from the tests performed to see if subjects have improvement in symptoms of heart failure. Participation in this study will last approximately 1 year to up to 7 years depending on randomization group. During the study period subjects will be asked to attend regular study visits with the research coordinator. These visits will include such activities as blood tests, questionnaires, physical evaluation by a study doctor, echocardiogram, and 6 minute hall walks. There will be a minimum of 10 or up to 15 planned research clinic visits. Subjects will have 1 overnight hospital stay for the study related RHC and research procedure. Each participant will receive a phone call between all study visits.

Subjects will have a 50:50 chance of receiving the Shunt during the randomization procedure (like the flip of a coin). Neither the subject, nor the blinded study doctor or blinded study coordinator will know which group subjects are in. Participants will be randomized to either the treatment group (and receive the Shunt) or the control group (and not receive the shunt). Neither the subject nor the study doctor will decide what group subjects are assigned.

Institution
MUSC
Recruitment Contact
Renee Baxley
843-792-1105
baxleyr@musc.edu

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study) Save

Date Added
November 12th, 2019
PRO Number
Pro00092860
Researcher
Edwin Smith

List of Studies


Profiles_link
Keywords
Autoimmune disease, Drug Studies, Immune System, Rare Diseases, Scleroderma, Stage III
Summary

The purpose of this study is to find out more information about the study drug iloprost for the treatment of symptomatic Raynaud's phenomenon (RP) attacks in people with scleroderma. A Raynaud's attack is defined as one where you notice at least one color change of your finger(s) (blue, white, or red) associated with at least one symptom (pain, numbness, tingling, and/or discomfort of the finger[s]). Your participation in this study will last approximately 9 weeks and will include 8 visits to the study center and 1 phone call from the study staff.

Institution
MUSC
Recruitment Contact
Nathan Wilson
843-792-8613
wilsonn@musc.edu

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) Save

Date Added
September 13th, 2019
PRO Number
Pro00092419
Researcher
John Kaczmar

List of Studies

Silhouette
Keywords
Cancer/Skin
Summary

This study is for patients with advanced squamous cell carcinoma of the skin. The purpose of this study is to see if adding a new drug called avelumab to another drug call cetuximab can increase the length of time patients are alive without their cancer getting worse.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Management of Patients Presenting with Acute Chest Pain Following Coronary Computed Tomography Angiography Save

Date Added
July 9th, 2019
PRO Number
Pro00087460
Researcher
Uwe o.p. Schoepf

List of Studies


Profiles_link
Keywords
Cardiovascular, Coronary Artery Disease
Summary

Patients who present to MUSC's Chest Pain Center with acute chest pain and have undergone coronary computerized tomography angiography or triple rule-out computed tomography imaging showing an intermediate stenosis will be prospectively selected. Consented patients will then have their clinical indicated coronary computerized tomography angiography or triple rule-out computed tomography imaging undergo an expedited computed tomography-fractional flow reserve analysis analysis. This analysis will be provided to Chest Pain Center physician of record to aid in downstream patient treatment decision making. Patients will then be followed-up at 3-months via telephone call and electronic medical records review.

Institution
MUSC
Recruitment Contact
Dante Giovagnoli
8438764922
giovagnd@musc.edu

Evaluation of the VISITAG SURPOINT™ Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH® SF and the THERMOCOOL SMARTTOUCH® Catheters for Pulmonary Vein Isolation (PVI) (SURPOINT COA) Save

Date Added
December 11th, 2018
PRO Number
Pro00083402
Researcher
Michael Field

List of Studies

Silhouette
Keywords
Cardiovascular
Summary

This study is for people who have Paroxysmal Atrial Fibrillation (PAF) and are undergoing an ablation. Atrial fibrillation (AFib) is a type of irregular heartbeat. If you have it, your doctor will classify yours by the reason for it and on how long it lasts. When your heartbeat returns to normal within 7 days, on its own or with treatment, it's known as paroxysmal atrial fibrillation. The purpose of this study is to provide additional information about the safety and effectiveness of the VISITAG SURPOINT™ Module with External Processing Unit (EPU) when used with a THERMOCOOL SMARTTOUCH® SF (STSF) and THERMOCOOL SMARTTOUCH® (ST) catheter. THERMOCOOL SMARTTOUCH® family of catheters have been approved for the treatment of PAF for people that have unsuccessfully tried antiarrhythmic drug treatment (medication used to correct irregular heart rhythm), due to drug intolerance/side-effects or ineffectiveness of the drugs in preventing PAF. Participation in the study will last approximately 12 months after the ablation procedure. There will be a 7-day phone call and study visits at 1 month, 3-month, 6-month, and 12-months after the ablation procedure to monitor the participant's health and arrhythmia status

Institution
MUSC
Recruitment Contact
Deborah Everidge
8437922244
adamsde@musc.edu

Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control Save

Date Added
December 1st, 2015
PRO Number
Pro00050157
Researcher
Raymond Anton

List of Studies


Profiles_link
Keywords
Alcohol, Brain, Substance Use
Summary

This study examines the effects of the medication tolcapone among individuals who regularly drink alcohol. Participants in this study will be randomly assigned to take either tolcapone or a matched placebo for 8 days. There are 3 study visits, including 2 MRI scans, and a debriefing session. This study does not involve alcohol treatment. Interested individuals must be referred for participation by the Charleston Alcohol Research Center Clinical Intake and Assessment Core. For more information, call 792-1222 or email alcoholstudy@musc.edu.

Institution
MUSC
Recruitment Contact
Charleston Alcohol Research Center
(843) 792-1222
alcoholstudy@musc.edu

Charleston ARC Clinical Project 4- Cortical rTMS as a tool to change craving and brain reactivity to alcohol cues Save

Date Added
December 1st, 2015
PRO Number
Pro00050256
Researcher
James Prisciandaro

List of Studies


Profiles_link
Keywords
Alcohol, Brain, Substance Use
Summary

This study examines the effects of non-invasive brain stimulation as a tool to change the brain's response to alcohol cues. There are 3 study visits. At each study visit participants will receive a single session of real or sham transcranial magnetic stimulation (TMS) followed by an MRI scan. This study does not involve alcohol treatment. Interested individuals must be referred for participation by the Charleston Alcohol Research Center Clinical Intake and Assessment Core. For more information, call 792-1222 or email alcoholstudy@musc.edu.

Institution
MUSC
Recruitment Contact
Charleston Alcohol Research Center
(843) 792-1222
alcoholstudy@musc.edu

Change_preferences

-- OR --

Create_login